These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Condliffe R; Kiely DG; Peacock AJ; Corris PA; Gibbs JS; Vrapi F; Das C; Elliot CA; Johnson M; DeSoyza J; Torpy C; Goldsmith K; Hodgkins D; Hughes RJ; Pepke-Zaba J; Coghlan JG Am J Respir Crit Care Med; 2009 Jan; 179(2):151-7. PubMed ID: 18931333 [TBL] [Abstract][Full Text] [Related]
10. Epidemiology and mortality of connective tissue disease-associated pulmonary arterial hypertension: A national cohort study in taiwan. Lin CY; Ko CH; Hsu CY; Chen HA Semin Arthritis Rheum; 2020 Oct; 50(5):957-962. PubMed ID: 32906031 [TBL] [Abstract][Full Text] [Related]
11. Connective tissue disease-related pulmonary arterial hypertension. Thakkar V; Lau EM Best Pract Res Clin Rheumatol; 2016 Feb; 30(1):22-38. PubMed ID: 27421214 [TBL] [Abstract][Full Text] [Related]
13. Pulmonary Hypertension in Connective Tissue Diseases Other than Systemic Sclerosis. Budhram B; Weatherald J; Humbert M Semin Respir Crit Care Med; 2024 Jun; 45(3):419-434. PubMed ID: 38499196 [TBL] [Abstract][Full Text] [Related]
14. Survival and prognostic factors in patients with connective tissue disease-associated pulmonary hypertension diagnosed by echocardiography: results from a Korean nationwide registry. Kang KY; Jeon CH; Choi SJ; Yoon BY; Choi CB; Lee CH; Suh CH; Lee CW; Cho CS; Nam EJ; Koh EM; Kim HY; Choi HJ; Kim HA; Jun JB; Lee J; Kim J; Ji JD; Min JK; Kim KJ; Shin K; So MW; Kwon SR; Kim SK; Nah SS; Kwok SK; Lee SK; Lee SW; Park SH; Park W; Park YB; Lee YH; Lee SS; Yoo DH Int J Rheum Dis; 2017 Sep; 20(9):1227-1236. PubMed ID: 26214170 [TBL] [Abstract][Full Text] [Related]
15. Pulmonary arterial hypertension in the setting of scleroderma is different than in the setting of lupus: A review. Bazan IS; Mensah KA; Rudkovskaia AA; Adonteng-Boateng PK; Herzog EL; Buckley L; Fares WH Respir Med; 2018 Jan; 134():42-46. PubMed ID: 29413506 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological management of connective tissue disease-associated pulmonary arterial hypertension. Kularatne M; Boucly A; Savale L; Solinas S; Cheron C; Roche A; Jevnikar M; Jaïs X; Montani D; Humbert M; Sitbon O Expert Opin Pharmacother; 2023; 24(18):2101-2115. PubMed ID: 37869785 [TBL] [Abstract][Full Text] [Related]
17. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Coghlan JG; Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; Kuwana M; McLaughlin VV; Peacock AJ; Simonneau G; Vachiéry JL; Blair C; Gillies H; Miller KL; Harris JHN; Langley J; Rubin LJ; Ann Rheum Dis; 2017 Jul; 76(7):1219-1227. PubMed ID: 28039187 [TBL] [Abstract][Full Text] [Related]
18. Pulmonary arterial hypertension related to connective tissue disease: a review. Ahmed S; Palevsky HI Rheum Dis Clin North Am; 2014 Feb; 40(1):103-24. PubMed ID: 24268012 [TBL] [Abstract][Full Text] [Related]
19. Nailfold microvascular abnormalities are associated with a higher prevalence of pulmonary arterial hypertension in patients with MCTD. Todoroki Y; Kubo S; Nakano K; Miyazaki Y; Ueno M; Satoh-Kanda Y; Kanda R; Miyagawa I; Hanami K; Nakatsuka K; Saito K; Nakayamada S; Tanaka Y Rheumatology (Oxford); 2022 Nov; 61(12):4875-4884. PubMed ID: 35285493 [TBL] [Abstract][Full Text] [Related]